Professor, Medicine, University of Maryland School of Medicine
Oncology
Dr. Kevin J. Cullen, MD
|
|
Give Review
Kevin Cullen practices Oncology. He went to Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School has a rank of 1 in research and a 12 in primary care He over the years received 2 awards: "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Kevin Cullen has written publications. He has 73 publications published with PubMed. The lastest publication is: 'Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer.' Kevin Cullen is registered with Medicare.
Publications
- Oropharyngeal Cancer (OPC) drives racial outcome disparities in squamous cell carcinoma of the head and neck (HNSCC): Ten year experience at the university of maryland...
- A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous Cell carcinoma of ...
- Emergence of HPV16 positive oropharyngeal Cancer in black patients over time: University of Maryland 1992-2007.
- The role of human papillomavirus in nongenital Cancers.
- Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell Cancer of the head and neck treated with definit...
- Role of Neurofilament Light Polypeptide in Head and Neck Cancer Chemoresistance.
- Impact of early percutaneous endoscopic gastrostomy tube placement on nutritional status and hospitalization in patients with head and neck Cancer receiving definitive...
- Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal Cancer: An analysis of the TAX 324 trial.
- Phase II Study Evaluating the Addition of Cetuximab to the Concurrent DeLivery of Weekly Carboplatin, Paclitaxel, and Daily Radiotherapy for Patients With Locally Adva...
- beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous Carcinoma of the head and neck: a compa...
- Racial survival disparity in head and neck Cancer results from low prevalence of human papillomavirus infection in black oropharyngeal Cancer patients.
- Elevated expression of glutathione S-transferase pi and p53 confers poor prognosis in head and neck Cancer patients treated with chemoradiotherapy but not radiotherapy...
- Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck Cancer.
- Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous Cell carcinoma: po...
- Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous Cell carcinoma Cell lines and primary tumors.
- Capecitabine induces rapid, sustained response in two patients with extensive oral verrucous Carcinoma.
- Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance.
- A happy outcome to a bad problem.
- The drug resistance proteins, multidrug resistance-associated protein and P-glycoprotein, do not confer resistance to Fas-induced Cell death.
- Mortality trends, 1965 to 1989, in Busselton, the site of repeated health surveys and interventions.
- Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast Cancer.
- The insulin-like growth factor binding protein BP-25 is expressed by human breast Cancer cells.
- The T61 human breast Cancer xenograft: an experimental model of estrogen therapy of breast Cancer.
- Ethnic differences in Cancer risk behaviors through the transition out of high school.
- Insulin-like growth factor II (IGF-II) immunohistochemistry in breast Cancer: relationship with the most important morphological and biochemical prognostic parameters.
- When is Helicobacter pylori infection acquired?
- IGF-I and IGF-II expression in human breast Cancer xenografts: relationship to hormone independence.
- Insulinlike growth factors in human malignancy.
- Endocrine therapy of human breast Cancer cells: the role of secreted polypeptide growth factors.
- Effect of endocrine therapy on growth of T61 human breast Cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-...
- Insulin-like growth factor II mRNA expression in human breast Cancer.
- IGF-II mRNA and protein are expressed in the stroma of invasive breast Cancers: an in situ hybridization and immunohistochemistry study.
- Insulin-like growth factor-1 and breast Cancer risk in postmenopausal African-American women.
- Stromal-epithelial interactions in breast Cancer.
- Insulin-like growth factor-II overexpression in MCF-7 Cells induces phenotypic changes associated with malignant progression.
- Stromal IGF-II messenger RNA in breast Cancer: relationship with progesterone receptor expressed by malignant epithelial cells.
- Insulin-like growth factors in human breast Cancer.
- Mammary tumor fibroblasts are phenotypically distinct from non-tumor fibroblasts.
- Molecular biomarkers in HNSCC: prognostic and therapeutic implications.
- Paracrine/autocrine regulation of breast Cancer by the insulin-like growth factors.
- Affinity for the insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast Cancer cells.
- The effect of extraCellular calcium on colonocytes: evidence for differential responsiveness based upon degree of Cell differentiation.
- Survival and human papillomavirus in oropharynx Cancer in TAX 324: a subset analysis from an international phase III trial.
- Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell Cancer of the head and neck: long-term ...
- Growth factor mRNA expression in human head and neck malignant Tumors.
- Coexpression of stromelysin-3 and insulin-like growth factor II in tumors of ectodermal, mesodermal, and endodermal origin: indicator of a fetal Cell phenotype.
- Transfected MCF-7 cells as a model for breast-Cancer progression.
- HER-2-targeted antisense oligonucleotide results in sensitization of head and neck Cancer cells to chemotherapeutic agents.
- Insulin-like growth factor expression in breast Cancer epithelium and stroma.
- Local feedback mechanisms in human breast Cancer.
- Complications from planned, posttreatment neck dissections.
- Cisplatin and fluorouracil alone or with docetaxel in head and neck Cancer.
- Insulin-like growth factor receptor expression and function in human breast Cancer.
- Growth factor messenger RNA expression by human Breast fibroblasts from benign and malignant lesions.
- Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck Cancer.
- Patterns of failure among patients with squamous Cell carcinoma of the head and neck who obtain a complete response to chemoradiotherapy.
- Glutathione content but not gamma glutamyl cysteine synthetase mRNA expression predicts cisplatin resistance in head and neck Cancer cell lines.
- Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck Cancer.
- Malignant Breast epithelium selects for insulin-like growth factor II expression in Breast stroma: evidence for paracrine function.
- Race impacts outcome in stage III/IV squamous Cell carcinomas of the head and neck after concurrent chemoradiation therapy.
- Sequential therapy for the locally advanced larynx and hypopharynx Cancer subgroup in TAX 324: survival, surgery, and organ preservation.
- Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck Cancer cell lines.
- Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck Cancer.
- Molecular markers predictive of response and prognosis in the patient with advanced squamous Cell carcinoma of the head and neck: evolution of a model beyond TNM staging.
- Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck Cancer.
- Insulin-like growth factor mediated stromal-epithelial interactions in human breast Cancer.
- Planned neck dissection for advanced primary head and neck malignancy treated with organ preservation therapy: Disease control and survival outcomes.
- Effect of zoledronic acid on oral fibroblasts and epithelial Cells: a potential mechanism of bisphosphonate-associated osteonecrosis.
- A novel bioassay model to determine clinically significant bisphosphonate levels.
- MMP-2 and MMP-9 expression in breast Cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions.
- GPx3 promoter hypermethylation is a frequent event in human Cancer and is associated with tumorigenesis and chemotherapy response.
- Next-Generation Sequencing-Based HPV Genotyping Assay Validated in Formalin-Fixed, Paraffin-Embedded Oropharyngeal and Cervical Cancer Specimens.
Schools
Harvard Medical School
Beth Israel Hospital
Hammersmith Hospital
National Cancer Institute
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Choice Advantage
- Blue Choice Network POS
- Blue Preferred PPO
- CareFirst Maryland POS
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- Geisinger Health Plan
- Golden Rule
- GEHA
- Choice Care PPO
- Kaiser Permanente
- Mail Handlers Benefit Plan (MHBP)
- Maryland Physicians Care
- MedHealthInsurance
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
National Institutes of Health Clinical Center -
Beth Israel Deaconess Medical Center -
Harvard Medical School
Hospital
-
University of Maryland Baltimore Washington Medical Center -
University of Maryland Medical Center
Drug Facts
| NPI NUMBER | 1225071236 | |
| NPPES Provider LastName | CULLEN | |
| NPPES Provider FirstName | KEVIN | |
| NPPES Provider ZIPCode | 212011544 | |
| NPPES Provider State | MD | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 96.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225071236 |
| Last Name Of The Provider | CULLEN |
| First Name Of The Provider | KEVIN |
| View All |
Similar Doctors
|
|
Dr. Christian F. Meyer, MD |
|
|
Dr. Paul C. Celano, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ephraim J. Fuchs, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Samuel R. Denmeade, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. David A. Riseberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paula M. Rosenblatt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carol A. Huff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. B D. Smith Jr., MD |